158 related articles for article (PubMed ID: 37708806)
1. Incident mental health episodes after initiation of gabapentinoids vs. dopamine agonists for early-onset idiopathic restless legs syndrome.
Costales B; Vouri SM; Brown JD; Setlow B; Goodin AJ
Psychiatry Res; 2023 Oct; 328():115479. PubMed ID: 37708806
[TBL] [Abstract][Full Text] [Related]
2. Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.
Hankin C; Lee D; Garcia-Borreguero D; Wang Z
J Clin Sleep Med; 2019 Sep; 15(9):1225-1232. PubMed ID: 31538593
[TBL] [Abstract][Full Text] [Related]
3. Treatment initiation and utilization patterns of pharmacotherapies for early-onset idiopathic restless legs syndrome.
Costales B; Vouri SM; Brown JD; Setlow B; Goodin AJ
Sleep Med; 2022 Aug; 96():70-78. PubMed ID: 35605349
[TBL] [Abstract][Full Text] [Related]
4. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
Garcia-Borreguero D; Kohnen R; Silber MH; Winkelman JW; Earley CJ; Högl B; Manconi M; Montplaisir J; Inoue Y; Allen RP
Sleep Med; 2013 Jul; 14(7):675-84. PubMed ID: 23859128
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
[TBL] [Abstract][Full Text] [Related]
6. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
[TBL] [Abstract][Full Text] [Related]
7. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
Van Den Eeden SK; Albers KB; Davidson JE; Kushida CA; Leimpeter AD; Nelson LM; Popat R; Tanner CM; Bibeau K; Quesenberry CP
Sleep; 2015 Jul; 38(7):1009-15. PubMed ID: 26083613
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonists and risk of lung cancer in patients with restless legs syndrome.
Hernandez-Con P; Shults J; Willis AW; Yang YX
Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):726-734. PubMed ID: 36760024
[TBL] [Abstract][Full Text] [Related]
9. Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.
Allen R; Oertel W; Walters A; Benes H; Schollmayer E; Grieger F; Moran K; Kohnen R
Sleep Med; 2013 Dec; 14(12):1375-80. PubMed ID: 24246378
[TBL] [Abstract][Full Text] [Related]
10. Restless legs syndrome/Willis Ekbom disease: evaluation and treatment.
Allen RP
Int Rev Psychiatry; 2014 Apr; 26(2):248-62. PubMed ID: 24892899
[TBL] [Abstract][Full Text] [Related]
11. Decline in dopamine agonists prescribing and characteristics of drugs prescribed during ambulatory office visits for restless legs syndrome: the National Ambulatory Medical Care Survey 2007-2015.
Kim J; Hartzema AG
Sleep Med; 2019 Feb; 54():238-243. PubMed ID: 30590306
[TBL] [Abstract][Full Text] [Related]
12. Higher prevalence of restless legs syndrome/Willis-Ekbom disease in multiple sclerosis patients is related to spinal cord lesions.
Minár M; Petrleničová D; Valkovič P
Mult Scler Relat Disord; 2017 Feb; 12():54-58. PubMed ID: 28283108
[TBL] [Abstract][Full Text] [Related]
13. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
Geyer J; Bogan R
Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
[TBL] [Abstract][Full Text] [Related]
14. High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.
Winkelman JW
Sleep; 2022 Feb; 45(2):. PubMed ID: 34417810
[TBL] [Abstract][Full Text] [Related]
15. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
[TBL] [Abstract][Full Text] [Related]
16. Differential Diagnoses of Restless Legs Syndrome/Willis-Ekbom Disease: Mimics and Comorbidities.
Chokroverty S
Sleep Med Clin; 2015 Sep; 10(3):249-62, xii. PubMed ID: 26329435
[TBL] [Abstract][Full Text] [Related]
17. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
18. [Restless legs syndrome - a review].
Sveinsson OA; Sigurdsson AP
Laeknabladid; 2012 Jan; 98(1):33-7. PubMed ID: 22253081
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dopamine agonists in restless legs syndrome.
Hornyak M; Trenkwalder C; Kohnen R; Scholz H
Sleep Med; 2012 Mar; 13(3):228-36. PubMed ID: 22281001
[TBL] [Abstract][Full Text] [Related]
20. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
Meyers J; Candrilli S; Allen R; Manjunath R; Calloway M
Manag Care; 2012 Oct; 21(10):44-51. PubMed ID: 23156076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
